News | January 06, 2026
PathoCare Holdings valued at $1.75 billion following major third-party tender offer
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The initiative is focused on a problem that continues to plague cancer outcomes in India
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
Subscribe To Our Newsletter & Stay Updated
